Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

ACT therapy

Roche Basel Switzerland

Price cut keeps Kadcyla on CDF

Comes after pressure from campaign groups

- PMLiVE

Merck and MacroGenics collaborate on immuno-oncology

Evaluates margetuximab with Keytruda for gastric cancer

Bristol-Myers Squibb (BMS) building

BMS pulls ahead of Merck in quarterly PD-1 inhibitor sales

Supports analysts prediction BMS' Opdivo will become market leader

- PMLiVE

Keytruda ups survival in lung cancer, misses secondary target

Data shows Keytruda fails to beat BMS' Opdivo

Merck & Co reorganises its HCP communities, hands Univadis to Physicians Interactive

Physicians Interactive outlines globalambitions for its newly-expanded network

Bristol-Myers Squibb (BMS) building

BMS gets OK for broader Opdivo use in lung cancer

US regulator'sdecision allows firm to edge in front of Merck & Co's Keytruda

National Institute for Health and Care Excellence NICE logo

NICE recommends Keytruda for advanced skin cancer

Second recommendation for drug in a week

Eli Lilly HQ

Lilly wins breakthrough designation for breast cancer drug

CDK 4 and 6 inhibitor Abemaciclib's development to be expedited by FDA

- PMLiVE

Merck gets lung cancer OK for Keytruda in US

Highlights increased understanding of molecular processes in cancer

MSD launches preventative healthcare accelerator

Joins forces with Wayra Open Future for VelocityHealth fund

Roche's Perjeta pertuzumab

Roche’s Perjeta launches in UK for early breast cancer

Says nearly 2,000 women each year could benefit from its drug

- PMLiVE

Merck gets first OK for once-weekly DPP-4 inhibitor

Marizev approved in Japan

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links